CMPX’s latest rating updates from top analysts.

Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on May 27 ’25. In the deal valued at $2.11 per share,10,000 shares were bought. As a result of this transaction, Schuetz Thomas J. now holds 6,480,825 shares worth roughly $15.62 million.

Then, GORDON CARL L sold 3,571,428 shares, generating $5,678,571 in total proceeds. Upon selling the shares at $1.59, the Director now owns 0 shares.

Before that, ORBIMED ADVISORS LLC sold 3,571,428 shares. Compass Therapeutics Inc shares valued at $5,678,571 were divested by the Director at a price of $1.59 per share. As a result of the transaction, ORBIMED ADVISORS LLC now holds 0 shares, worth roughly $0.0.

Leerink Partners upgraded its Compass Therapeutics Inc [CMPX] rating to an Outperform from a a Market perform in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late February with a ‘”a Buy”‘ rating. Piper Sandler began covering CMPX with “an Overweight” recommendation on February 19, 2025. D. Boral Capital started covering the stock on December 23, 2024. It rated CMPX as “a Buy”.

Price Performance Review of CMPX

On Friday, Compass Therapeutics Inc [NASDAQ:CMPX] saw its stock unchanged to $2.41. Over the last five days, the stock has lost -3.60%. Compass Therapeutics Inc shares have risen nearly 66.21% since the year began. Nevertheless, the stocks have risen 97.54% over the past one year. While a 52-week high of $4.08 was reached on 02/11/25, a 52-week low of $0.76 was recorded on 04/01/25.

Levels Of Support And Resistance For CMPX Stock

The 24-hour chart illustrates a support level at 2.32, which if violated will result in even more drops to 2.23. On the upside, there is a resistance level at 2.46. A further resistance level may holdings at 2.52.

How much short interest is there in Compass Therapeutics Inc?

A steep rise in short interest was recorded in Compass Therapeutics Inc stocks on 2025-05-30, dropping by -0.2 million shares to a total of 7.43 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 7.63 million shares. There was a decline of -2.65%, which implies that there is a negative sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.